Finance

Beta
Lists
068270:KRX
Celltrion Inc
â‚©167,300.00
-1.59%
(-2,700.00) 1D
Jun 10, 3:30:24 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 068270...
Open
â‚©165,100
High
â‚©168,400
Low
â‚©162,700
Mkt. cap
38.91T
Avg. vol.
712.94K
Volume
527.94K
Dividend
0.43%
Quarterly dividend
â‚©179
Ex-dividend date
Dec 29, 2025
P/E ratio
30.44
52-wk high
â‚©239,047
52-wk low
â‚©150,571
EPS
â‚©5,496
Shares outstanding
221.63M
No. of employees
3K
Open
â‚©165,100
High
â‚©168,400
Low
â‚©162,700
Mkt. cap
38.91T
Avg. vol.
712.94K
Volume
527.94K
Dividend
0.43%
Quarterly dividend
â‚©179
Ex-dividend date
Dec 29, 2025
P/E ratio
30.44
52-wk high
â‚©239,047
52-wk low
â‚©150,571
EPS
â‚©5,496
Shares outstanding
221.63M
No. of employees
3K
News stories
From sources across the web
Profile
Celltrion, Inc. is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea. Seo Jung-jin, its founder was awarded the 2021 EY World Entrepreneur Of The Year. Wikipedia
About Celltrion Inc
CEOWoosung Kee
Employees2.68K
Founded2002
Headquarters-
SectorBiotechnology
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
961.46B
1.03T
1.33T
1.14T
Cost of goods sold
417.11B
402.86B
476.46B
459.14B
Cost of revenue
417.11B
402.86B
476.46B
459.14B
Research and development expenses
-
-
210.70B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
301.89B
324.69B
3.23B
363.97B
Operating expense
301.28B
324.69B
383.06B
363.97B
Total operating expenses
718.39B
727.56B
859.52B
823.12B
Operating income
243.07B
301.41B
470.64B
321.87B
Other non operating income
-90.71B
-17.89B
1.02B
-6.34B
EBT including unusual items
52.43B
377.94B
527.86B
432.20B
EBT excluding unusual items
52.43B
378.19B
528.09B
432.23B
Income tax expense
-10.87B
46.02B
-64.71M
82.35B
Effective tax rate
-20.74%
12.18%
-0.01%
19.05%
Other operating expenses
-
-
93.27B
-
Net income
61.17B
331.35B
528.43B
346.14B
Net profit margin
6.36%
32.20%
39.73%
30.23%
Earnings per share
262.86
1.44K
2.28K
1.50K
Interest and investment income
5.50B
4.75B
5.40B
6.19B
Interest expense
-19.00B
-18.08B
-21.35B
-26.72B
Net interest expenses
-13.49B
-13.34B
-15.95B
-20.53B
Depreciation and amortization charges
-
-
17.16B
-
EBITDA
319.79B
374.56B
537.36B
398.40B
Gain or loss from assets sale
1.30M
-150.99M
16.25M
5.84M
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more